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Traumatic injuries of peripheral nerves represent common casualties 
and their social impact is considerably high. Although peripheral 
nerves retain a good regeneration potential, the clinical outcome after 
nerve lesion is far from being satisfactory and functional recovery is 
almost never complete, especially in the case of large nerve defects, 
that result in loss or diminished sensitivity and/or motor activity of 
the innervated target organs. Therefore, to improve the outcome after 
nerve damage, or in peripheral neuropathies, there is a need for fur-
ther research in nerve repair and regeneration to identify factors that 
promote axonal regrowth, remyelination and target reinnervation. 
Among the different factors involved in these processes (Taveggia 
et al., 2010; Pereira et al., 2012), stands out neuregulin 1 (NRG1), a 
factor which plays a role both in the myelination occurring during 
development (Lemke, 2006) and in the response to peripheral 
nerve injury (Syed and Kim, 2010; Fricker and Bennett, 2011). 
NRG1 is a pleiotropic factor characterized by the existence of nu-
merous isoforms arising from alternative splicing of exons that confer 
to the protein with deeply different characteristics (Falls, 2003; Mei 
and Xiong, 2008). 
NRG1 can be produced as a secreted or as a transmembrane 
protein ready to interact with its receptor, or as a transmembrane 
pro-protein that needs a proteolytic cleavage to release a soluble frag-
ment or to protrude its receptor binding domain in the extracellular 
environment (Figure 1). According to its structure, NRG1 signals in 
a paracrine, autocrine or juxtacrine manner; moreover, juxtacrine in-
teractions can signal both in a forward and reverse manner due to the 
production of a fragment containing the intracellular domain (ICD, 
Figure 1B) that can translocate into the nucleus and influence gene 
transcription (Bao et al., 2003; Bao et al., 2004; Chen et al., 2010). 
NRG1 interacts directly with two of the four members of the tyrosine 
kinase receptor family ErbB: ErbB4, that signals as homo or heterodi-
mer, and ErbB3, that forms a heterodimer with ErbB2. 
In the peripheral nervous system, NRG1 soluble isoforms are 
mainly released by Schwann cells, while transmembrane isoforms are 
mainly expressed by the axon and both interact with the heterodimer 
receptor ErbB2-ErbB3, generally expressed by Schwann cells. NRG1 
plays an important role both in the myelination occurring during 
development and in the different phases occurring after injury in the 
peripheral nerve: axon degeneration, axon regrowth, remyelination 
and target reinnervation (Taveggia et al., 2010; Fricker and Bennett, 
2011; Pereira et al., 2012; Salzer, 2012; Gambarotta et al., 2013; Heer-
mann and Schwab, 2013). 
These processes respond to different cues, as can be inferred from 
the analysis of transgenic mice models summarized in Figure 2. The 
difference between the myelination process occurring during devel-
opment and the regeneration process occurring after nerve injury is 
underlined by the fact that soluble NRG1 isoforms play an import-
ant role after nerve injury, while their lack seems irrelevant during 
development.
Membrane bound NRG1 determinates the myelination fate during 
development 
During development, the absence of soluble NRG1 in Schwann cells 
does not affect myelination (Stassart et al., 2013) and, accordingly, 
soluble NRG1 over-expression in motoneurons and dorsal root gan-
glia (DRG) neurons does not influence myelination (Michailov et al., 
2004).
Conversely, axonal transmembrane NRG1 expression level deter-
mines the myelination fate of axons and the thickness of the myelin 
sheath: animals lacking axonal transmembrane NRG1 show hypo-
myelination (Michailov et al., 2004; Taveggia et al., 2005), while its 
over-expression causes hypermyelination (Michailov et al., 2004) and 
conversion of normally non-myelinated neurons to myelinated neu-
rons (Taveggia et al., 2005). 
Soluble and membrane bound NRG1 play different roles after 
peripheral nerve injury
Animals lacking soluble NRG1 in Schwann cells display peripheral 
nerve regeneration severely impaired (Stassart et al., 2013). Accord-
ingly, soluble NRG1 over-expression in motoneurons and dorsal root 
ganglion neurons improves remyelination after injury (Stassart et al., 
2013). 
Immediately after injury, we (unpublished results) and others 
(Stassart et al., 2013) observed that the soluble NRG1 transcript is 
strongly upregulated in the distal and proximal nerve. Because RNA 
extracted from the nerve belongs mainly to Schwann cells, this obser-
vation suggests that Schwann cells, following nerve injury, produce 
high amounts of soluble NRG1 that could stimulate, in an autocrine 
manner, Schwann cell survival and, likely, migration of macrophages 
that remove myelin debris in the early phases of Wallerian degenera-
tion to allow remyelination (Fricker and Bennett, 2011). 
The soluble NRG1 upregulation observed in Schwann cells im-
mediately after nerve injury suggests that denervated Schwann cells 
require autocrine stimulation with soluble NRG1 for survival and 
that the peripheral nerve regeneration impairment observed in 
animals lacking Schwann cell derived soluble NRG1 is the indirect 
consequence of problems occurring during the early phases of axon 
degeneration and axon regrowth, not during the following phases of 
remyelination and target reinnervation. 
Animals lacking axonal transmembrane NRG1 isoforms show 
an impaired rate of remyelination and functional recovery at early 
phases after nerve injury; at later stages, the myelination thickness is 
not strictly dependent on axonal NRG1 and it has been hypothesized 
a compensation effect mediated by other factors (Fricker et al., 2013). 
Accordingly, axonal transmembrane NRG1 over-expression improves 
peripheral nerve regeneration (Stassart et al., 2013). 
Strategies to promote nerve regeneration
These observations suggest that soluble NRG1 plays a role during the 
early phases following nerve injury corresponding to axon degener-
ation and regrowth, while transmembrane NRG1 plays a role during 
later phases corresponding to the remyelination process. Therefore, 
soluble NRG1, already used in human trials for heart failure treat-
ment, could be an effective therapeutic candidate to promote nerve 
regeneration. Accordingly, it has been already demonstrated that 
nerve regeneration is successfully promoted by subcutaneous NRG1 
injection (Chen et al., 1998; Yildiz et al., 2011), by NRG1 released by 
biomaterials (Mohanna et al., 2003; Cai et al., 2004; Mohanna et al., 
2005) or by adenovirus encoded NRG1 (Joung et al., 2010). More-
over, it has been suggested that NRG1 is released by the degenerating 
muscle successfully used to fill a non-nervous conduit graft consisting 
of a vein to bridge the proximal and the distal stumps after substance 
loss (Nicolino et al., 2003).
However, we think that treatment with recombinant soluble NRG1 
should be carried out in a well-defined time window, during early 
phases following nerve injury, to improve survival, migration and 
redifferentiation of Schwann cells, in synergy with endogenous NRG1 
released by Schwann cells immediately after injury, that in cases of 
severe damage may not be sufficient. 
Furthermore, NRG1 treatment should be finely regulated, because 
it has been demonstrated in vitro that different NRG1 isoforms have 
different pro-myelinating activities and a too high concentration can 
inhibit myelination (Syed et al., 2010). 
A second strategy to promote myelination could be the over-ex-
pression of recombinant transmembrane NRG1 in axons during later 
phases following nerve injury. However, to express transmembrane 
isoforms, the use of viral vectors would be necessary; to bypass this 
critical step, manipulation of the processing of endogenously ex-
pressed NRG1 could increase its pro-myelinating activity. Actually, 
Neuregulin 1 isoforms could be an 
effective therapeutic candidate to 
promote peripheral nerve regeneration
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Figure 1 Structure of soluble or transmembrane neuregulin 1 (NRG1) isoforms. 
NRG1 isoforms are tissue-specifically expressed and are classified into types I–VI according to their N-terminus domain, and into types α/β, 1–4, 
a–c, according to their C-terminus domains, as previously shown (Falls, 2003; Mei and Xiong, 2008). To simplify, in this figure only soluble (type 
I–II) and transmembrane (type III) NRG1 isoform structures are shown, because type IV–VI role in the peripheral nerve is still not known.
All NRG1 isoforms contain an epidermal growth factor (EGF)-like domain (here in black). Panel A: Soluble NRG1 contain a type I or 
type II N-terminal domain, an immunoglobulin (Ig)-like domain and can be expressed as secreted proteins released in the extracellular 
environment (type β3) or as transmembrane pro-proteins susceptible to proteolytic shedding and consequent release of the soluble li-
gand in the extracellular environment.  Panel B: Transmembrane NRG1 are characterized by the presence of a type III N-terminal domain, 
containing a cystein rich domain (CRD) and can be expressed with the EGF-like domain ready to interact with receptors (type β3) or as 
transmembrane pro-protein that requires a proteolytic cleavage to expose the EGF-like domain towards receptors. These isoforms can be 
cleaved by either the α secretase TACE or the β secretase BACE1, and by a γ secretase that releases an NRG1 intracellular domain (ICD).
Soluble NRG1 Transmembrane NRG1
Figure 2 The role played by soluble and transmembrane 
neuregulin 1 (NRG1) isoforms in the myelination occurring 
during development and in the different phases occurring 
after nerve injury (axon degeneration, axon regeneration, 
remyelination and target reinnervation) as inferred from 
transgenic and conditional knockout mice. 
The absence of soluble NRG1 in Schwann cells does not affect 
myelination during development (+), but nerve regeneration is 
severely impaired (–) (Stassart et al., 2013). The over-expression 
of soluble NRG1 in motoneurons and dorsal root ganglia neurons 
does not affect myelination (+) during development (Michailov 
et al., 2004), but improves nerve regeneration after injury (++) 
(Stassart et al., 2013). Animals lacking axonal transmembrane 
NRG1 show hypomyelination (–) (Michailov et al., 2004; Taveggia 
et al., 2005) and an impaired rate of peripheral nerve regeneration 
(–) (Fricker et al., 2013). Animals over-expressing axonal trans-
membrane NRG1 show hypermyelination (++) (Michailov et al., 
2004; Taveggia et al., 2005) and an improvement of peripheral 
nerve regeneration (++) after nerve injury (Stassart et al., 2013).
transmembrane NRG1 can be cleaved by different metalloproteases, 
including the α secretase TACE (also known as ADAM17) and the β 
secretase BACE1, and other not yet identified proteases, that cleave 
the transmembrane NRG1 in the same stalk region, leaving the EGF-
like domain exposed and C terminal domains that differ by a few 
amino acids (Figure 1).
The effect on myelination of these proteases seems to be opposite: 
the β secretase BACE1 cleavage activates the pro-myelinating activity 
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of NRG1, as shown in BACE1 knockout mice characterized by an hy-
po-myelination phenotype (Willem et al., 2006; Hu et al., 2008) and 
in transgenic mice over-expressing a recombinant NRG1 mimicking 
the BACE1 cleavage, characterized by an hyper-myelinated pheno-
type (Velanac et al., 2012). It would be interesting to analyze the 
remyelination efficiency in these mice, to understand if BACE1 plays 
a role only during developmental myelination or also during remye-
lination occurring after peripheral nerve injury and repair. However, 
a pro-myelinating strategy including the treatment with BACE1 
stimulators, if any, would not be recommended, because BACE1 is a 
major drug target for Alzheimer’s disease: BACE1-mediated cleavage 
of amyloid precursor protein (APP) is the first step in the generation 
of the pathogenic amyloid-β peptides and recent studies demonstrate 
a wide range of BACE1 physiological substrates and functions (Vassar 
et al., 2014). 
Conversely, the α secretase TACE cleavage inhibits the pro-my-
elinating activity of NRG1 and its inactivation in motor neurons 
–obtained through conditional knockout mice–correlates with a 
hyper-myelination phenotype during development and in the adult 
(La Marca et al., 2011). No data concerning remyelination efficiency 
following peripheral nerve injury in mice in which TACE is inacti-
vated or inhibited by pharmacological treatments are available and it 
would be really useful to test if TACE inactivation promotes remye-
lination during peripheral nerve regeneration. 
Different TACE inhibitors are already available and used in 
preclinical trials anti rheumatoid arthritis and anti breast cancer 
(DasGupta et al., 2009; Rego et al., 2014) and could be useful tools to 
promote remyelination.
Because regeneration is spontaneous, but often incomplete, the 
development of new strategies to promote peripheral nerve regen-
eration is a significant goal to achieve, and the pleiotropic NRG1 
isoforms appear to be good candidates for therapeutic treatments.
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